2021 global humic-based biostimulants market analysis
The global humic-based biostimulants market size is projected to reach approximately USD 1,024.5million by 2028, at a CAGR of 9.45% from 2021 to 2028.
Read MoreIndustry analysis of medical healthcare, including drugs, medical devices, medical theraphy, etc.
The global humic-based biostimulants market size is projected to reach approximately USD 1,024.5million by 2028, at a CAGR of 9.45% from 2021 to 2028.
Read MoreThe global medical device cleaning market size is projected to reach USD 41.0 million by 2026, with ~72% CAGR during the forecast period.
Read Morethe global cell line development market is expected to register a CAGR of~12.5 from 2021 to 2027 and hold a value of ~USD 10,700million by 2027.
Read Morethe global CNS biomarkers market is expected to register a CAGR of~13.0%from 2021 to 2027and hold a value of over ~USD 7,500 million by2027.
Read MoreThe global cell banking outsourcing market is expected to register a CAGR of ~15.6% during the forecast period of 2021 to 2027 and is expected to reach ~USD 9,476.9 million by 2027.
Read MoreThe major factors driving the growth of the biometric-as-a-service market are the growing demand for cost-effective solutions to access advanced biometrics capabilities and rising government initiatives.
Read MoreAccording to the World Stroke Organization (WSO)’s Global Stroke Fact Sheet 2019, 13 million new cases of stroke are diagnosed globally every year, and over 80 million people who have experienced a stroke are currently living.
Read Morehe rate of cancer incidences in China is exploding very rapidly. China’s cancer treatment drug market continues rising owing to the increasing prevalence of various types of cancer, changing lifestyle & dietary habits, growing aging population.
Read MoreIn recent years, the incidence of thrombopenia in China keeps increasing. Thrombopenia is often seen in hematologic diseases such as primary immune thrombopenia, leukemia and aplastic anemia as well as in connective tissue diseases, liver diseases and tumor chemotherapy. Thrombopenia may also be congenital or drug induced. Primary immune thrombopenia is a clinically common hemorrhagic disease, accounting for 1/3 of hemorrhagic diseases. The annual incidence of primary immune thrombopenia is 5/100,000 to 10/100,000. The number of patients with thrombopenia in China is increasing by over 100,000 every year. Research shows…
Read MoreIndia is among the highest 20 global markets for medical devices; the market is predicted to extend at a 35.4% CAGR to succeed in Rs. 352,450 (US$ 50 billion) in 2025 from Rs. 77,539 crore (US$ 11 billion) in 2020.
Read More